Recent changes in serum tumor markers in non-small cell lung cancer patients after radioactive 125I seeds implantation
10.3969/j.issn.1000-8179.20130822
- VernacularTitle:非小细胞肺癌患者放射性125I粒子植入治疗后近期血清肿瘤标志物变化
- Author:
Jingkui YANG
;
Jinshuang LU
;
Guangjun ZHENG
;
Weiliang YAN
- Publication Type:Journal Article
- Keywords:
non-small cell lung cancer;
radioactive 125I seed;
CEA;
CA125;
SCC-Ag;
CYFRA21-1
- From:
Chinese Journal of Clinical Oncology
2014;(1):64-67
- CountryChina
- Language:Chinese
-
Abstract:
Objective:This study aimed to observe the clinical efficacy of implanting radioactive 125I seeds to treat non-small cell lung cancer (NSCLC) on the basis of the recent changes in serum tumor markers (including CEA, CA125, SCC-Ag, and CYFRA21-1). Methods:We selected 72 patients who were pathologically confirmed with NSCLC and received CT-guided percutaneous implantation of radioactive 125I seeds from January 2009 to June 2012. The concentration of the serum tumor markers was detected 3 d before implan-tation and 1, 2, 3, and 6 months after implantation. Result:All of the operations were successfully completed. One month after implan-tation, a significant change was observed in the concentration of serum tumor markers (CEA, CA125, SCC-Ag, and CYFRA21-1) com-pared with their preoperative levels (P<0.01). No significant difference was observed between the different time points after implanta-tion. Conclusion:The treatment of NSCLC by implanting radioactive 125I seeds can effectively reduce the level of tumor markers. A sig-nificant difference was observed in the level of tumor markers between patients with different efficacy classifications.
